

10/523,147

=> d his

(FILE 'HOME' ENTERED AT 13:07:18 ON 14 DEC 2007)

FILE 'REGISTRY' ENTERED AT 13:07:32 ON 14 DEC 2007

L1 STRUCTURE UPLOADED
L2 44 S L1
L3 STRUCTURE UPLOADED
L4 26 S L3
L5 946 S L1 SSS FUL
L6 545 S L3 SUB=L5 FUL
L7 540 S L6 AND CAPLUS/LC
L8 5 S L6 NOT L7

FILE 'CAPLUS' ENTERED AT 13:19:34 ON 14 DEC 2007

L9 5 S L6

=> d ibib abs hitstr total

L9 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:3857 CAPLUS

DOCUMENT NUMBER: 145:201947

TITLE: General and independent approaches to predict hERG affinity values

AUTHOR(S): Fioravanzo, Elena; Cazzolla, Nicola; Durando, Lucia; Ferrari, Cristina; Mabilia, Massimo; Ombrato, Rosella; Parenti, Marco Daniele

CORPORATE SOURCE: S-IN Soluzioni Informatiche, Vicenza, 36100, Italy
SOURCE: Internet Electronic Journal of Molecular Design (2005), 4(9), 625-646

CODEN: IEJMAT; ISSN: 1538-6414

URL: ftp://biochempress.com/iejmd_2005_4_0625.pdf

PUBLISHER: BioChem Press

DOCUMENT TYPE: Journal; (online computer file)

LANGUAGE: English

AB The protein product of the human ether-a-go-go gene (hERG) is a potassium channel that when inhibited may lead to cardiac arrhythmia. At present, various in vivo and in vitro models for QT prolongation and subsequent arrhythmia exist but they may not be entirely predictive for humans. Consequently, a fast and reliable in silico model to assess hERG affinity values would increase the screening rate and would also lower the cost compared to exptl. assay methods. Several approaches were employed to predict hERG K⁺ channel affinities. Different QSAR models were developed employing various mol. descriptors. Independent software (EVA, DRAGON, LigPrep, PASS (Prediction of Activity Spectra for Substances), and QikProp) was used to predict hERG activity values. QikProp predicts pharmaceutically relevant properties for organic mols., starting from their 3D structures and employing calculated phys. significant descriptors. In addition to cell permeability, logP, solubility, blood/brain barrier permeability, the program can also predict hERG K⁺ channel affinity values. PASS PRO (Prediction of Activity Spectra for Substances), a program that can predict several hundred biol. activity probability values, such as pharmacol. effects, mechanisms of action, toxicity, and metabolism reactions, was trained to predict the probability of hERG activity. The availability of different and independent methods and models able to predict hERG activity allows the application of a consensus criterion to be used as a filter in the discovery process. Five QSAR models were obtained with Q² values ranging from 0.65 to 0.98 and SDEP values ranging from 1.2 to 0.9. Employing QikProp, PASS, and QSAR predictions together, a consensus criterion was obtained that applied to 67 mols. yields a Matthews correlation coefficient (MCC) = 0.71, 5 false positives, and 3 false negatives. In the light of such result, our consensus score can be used as a powerful in silico screening for drug discovery processes.


IT 904286-10-8

RL: ADV (Adverse effect, including toxicity); DMA (Drug mechanism of action); PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (QSAR and software predictions of hERG potassium channel affinities of organic compds. and consensus criterion used for in silico screening for drug discovery processes)

RN 904286-10-8 CAPLUS

CN 2-Piperazinol, 2,4-dimethyl-1-(2-methyl-10H-thieno[2,3-b][1,5]benzodiazepin-4-yl)- (CA INDEX NAME)

10/523,147



REFERENCE COUNT:

12

THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1326876 CAPLUS

DOCUMENT NUMBER: 144:81049

TITLE: Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: A potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapine

AUTHOR(S): Rasmussen, Kurt; Benvenaga, Mark J.; Bymaster, Frank P.; Calligaro, David O.; Cohen, Ilene R.; Falcone, Julie F.; Hemrick-Luecke, Susan K.; Martin, Fionna M.; Moore, Nicholas A.; Nisenbaum, Laura K.; Schaus, John M.; Sundquist, Sarah J.; Tupper, David E.; Wiernicki, Todd R.; Nelson, David L.

CORPORATE SOURCE: Lilly Research Laboratories, Eli Lilly and Co., Indianapolis, IN, USA

SOURCE: Journal of Pharmacology and Experimental Therapeutics (2005), 315(3), 1265-1277

CODEN: JPETAB; ISSN: 0022-3565

PUBLISHER: American Society for Pharmacology and Experimental Therapeutics

DOCUMENT TYPE: Journal

LANGUAGE: English

AB FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene] is a potential novel antipsychotic with high affinity for dopamine D2 (K_i = 6.3 nM), 5-HT2A (K_i = 7.3 nM), and 5-HT6 (K_i = 8.0 nM) human recombinant receptors and lower affinity for histamine H1 (K_i = 30 nM) and 5-HT2C (K_i = 102 nM) human recombinant receptors than olanzapine. Oral administration of FMPD increased rat nucleus accumbens 3,4-dihydroxyphenylacetic acid concns. (ED200 = 6 mg/kg), blocked 5-HT2A agonist-induced increases in rat serum corticosterone levels (ED50 = 1.8 mg/kg), and inhibited the ex vivo binding of [125I]SB-258585 [4-iodo-N-[4-methoxy-3-(4-methyl-piperazin-1-yl)-phenyl]-benzenesulfonamide] to striatal 5-HT6 receptors (ED50 = 10 mg/kg) but failed to inhibit ex vivo binding of [3H]pyrilamine to hypothalamic histamine H1 receptors at doses of up to 30 mg/kg. In electrophysiol. studies, acute administration of FMPD selectively elevated the number of spontaneously active A10 (vs. A9) dopamine neurons and chronic administration selectively decreased the number of spontaneously active A10 (vs. A9) dopamine neurons. FMPD did not produce catalepsy at doses lower than 25 mg/kg p.o. In Fos-induction studies, FMPD had an atypical antipsychotic profile in the striatum and nucleus accumbens and increased Fos expression in orexin-containing neurons of the hypothalamus. FMPD produced only a transient elevation of prolactin levels. These data indicate that FMPD is an orally available potent antagonist of dopamine D2, 5-HT2A, and 5-HT6 receptors and a weak antagonist of H1 and 5-HT2C receptors. FMPD has the potential to have efficacy in treating schizophrenia and bipolar mania with a low risk of treatment-emergent extrapyramidal symptoms, prolactin elevation, and weight gain. Clin. trials are needed to test these hypotheses.

IT 660864-26-6

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (preclin. pharmacol. of antipsychotic FMPD with lower histamine H1 receptor affinity than olanzapine)


RN 660864-26-6 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 8-fluoro-4-[(3S)-3-(2-methoxyethyl)-

10/523,147

4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

63

THERE ARE 63 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:143137 CAPLUS

DOCUMENT NUMBER: 140:199351

TITLE: Preparation of piperazine-substituted aryl-fused benzodiazepines as dopamine D2 receptor antagonists for treating psychosis and bipolar disorders

INVENTOR(S): Aicher, Thomas Daniel; Chen, Zhaogen; Le Huerou, Yvan; Martin, Fionna Mitchell; Pineiro-Nunez, Marta Maria; Rocco, Vincent Patrick; Ruley, Kevin Michael; Schaus, John Mehnert; Spinazze, Patrick Gianpietro; Tupper, David Edward

PATENT ASSIGNEE(S): Eli Lilly and Company, USA; Le Huerou, Yvan

SOURCE: PCT Int. Appl., 340 pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014895	A1	20040219	WO 2003-IB3583	20030728
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003264915	A1	20040225	AU 2003-264915	20030728
EP 1546134	A1	20050629	EP 2003-784411	20030728
EP 1546134	B1	20070502		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AT 361289	T	20070515	AT 2003-784411	20030728
ES 2285227	T3	20071116	ES 2003-3784411	20030728
US 2006084643	A1	20060420	US 2005-523147	20051018
PRIORITY APPLN. INFO.:			US 2002-401297P	P 20020805
			WO 2003-IB3583	W 20030728
OTHER SOURCE(S):	MARPAT 140:199351			
GI				



AB Described herein are piperazine-substituted aryl-fused benzodiazepines (shown as I; variables defined below; e.g. (S)-10-[3-(2-methoxyethyl)piperazin-1-yl]-2-ethyl-4H-3-thia-1,4,9-triazabenzofazulene (shown as II)) and all salts, solvates, optical and geometric isomers, and crystalline forms thereof. For I: A is an optionally benzo-fused five or six member aromatic ring having 0-3 hetero atoms = N, S, and O; Alk is (C1-4) alkylene or hydroxy substituted (C1-4) alkylene; X is O or S; R1 is H, (C1-6) fluoroalkyl, (C3-6) cycloalkyl, or (C1-4) alkyl, wherein the (C1-4) alkyl is (un)substituted with hydroxy, methoxy, ethoxy, OCH₂CH₂OH, or -CN. R2 is H, halogen, (C1-6) fluoroalkyl, (C1-6) cycloalkyl, OR4, SR4, NO2, CN, COR4, C(O)OR4, CONR5R6, NR5R6, SO₂NR5R6, NR5COR4, NR5SO₂R4, (un)substituted aromatic, or (C1-6) alkyl, wherein (C1-6) alkyl is (un)substituted with a hydroxy group; R3 is H, (C1-6) fluoroalkyl, (C2-6) alkenyl, Ar, (C1-4)alkyl-Ar, or (C1-4) alkyl wherein (C1-4) alkyl is (un)substituted with a Ph. R4 is H, (C1-6) alkyl, (C1-6) fluoroalkyl, or (un)substituted aromatic; R5 and R6 = H, (C1-6) alkyl, or (un)substituted aromatic; R7 is H, (C1-6) alkyl, (C1-6) fluoroalkyl, or (un)substituted aromatic; R8 and R9 = H, (C1-6) alkyl, or (un)substituted aromatic; Ar is (un)substituted Ph, naphthyl, monocyclic heteroarom. or bicyclic heteroarom.; Z1 and Z2 = H, halogen, (C1-6) alkyl, (C1-6) fluoroalkyl, OR7, SR7, NO2, CN, COR7, CONR8R9, NR8R9, and (un)substituted aromatic. Also described are the use of I as antagonists of the dopamine D2 receptor and as agents for the treatment of psychosis and bipolar disorders, and pharmaceutical formulations of I. Relative D2 receptor binding affinities for .apprx.50 examples of I are tabulated, e.g. K_i <10 nM for II, i.e. greater affinity than that of clozapine or olanzapine. Compds. I exhibit a desirable level of 5-HT_{2A} affinity (no data). Compds. I have reduced propensity to cause weight gain because of their decreased affinity for the H₁ receptor, e.g. (S)-10-[3-(2-methoxyethyl)-4-methylpiperazin-1-yl]-2-

isopropyl-4H-3-thia-1,4,9-triazabenzofazulene dihydrochloride exhibits a 9:91 ratio of Ki values (nM) for D2:H1 receptors. Although the methods of preparation are not claimed, .apprx.400 example preps. of I and intermediates are included. For example, II was prepared from 2-ethyl-4,9-dihydro-3-thia-1,4,9-triazabenzofazulene-10-thione by adding MeOTf and after complete reaction adding (2S)-(2-methoxyethyl)piperazine in pyridine. The thione was prepared by cyclization of N-(2,4-dioxo-2,3,4,5-tetrahydro-1H-benzob[1,4]diazepin-3-yl)propionamide in the presence of Lawesson's reagent in 1,2-dichloroethane; the propionamide was prepared by acylation of 3-amino-1H-1,5-benzodiazepine-2,4-(3H,5H)-dione with propionyl chloride in DMF in the presence of Et3N.

IT 660865-47-4P

RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent); USES (Uses) (drug candidate, chromatog. resolution; preparation of


piperazine-substituted

aryl-fused benzodiazepines as dopamine D2 receptor antagonists for treating psychosis and bipolar disorders)

RN 660865-47-4 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-(2-methoxypropyl)-1-piperazinyl]-2-(1-methylethyl)- (CA INDEX NAME)

Absolute stereochemistry.



IT 660865-50-9P

RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)

(drug candidate, chromatog. resolution; preparation of


piperazine-substituted

aryl-fused benzodiazepines as dopamine D2 receptor antagonists for treating psychosis and bipolar disorders)

RN 660865-50-9 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-(2-methoxypropyl)-4-methyl-1-piperazinyl]-2-(1-methylethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

IT 660865-63-4P


RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)

(drug candidate, diastereomer separation by chromatog.; preparation of piperazine-substituted aryl-fused benzodiazepines as dopamine D2 receptor antagonists for treating psychosis and bipolar disorders)

RN 660865-63-4 CAPLUS

CN 2-Piperazineethanol, α -methyl-4-(2-methyl-10H-thieno[2,3-b][1,5]benzodiazepin-4-yl)-, dihydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

IT 660865-54-3P 660865-55-4P

RL: PAC (Pharmacological activity); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES


(Uses)

(drug candidate; preparation of piperazine-substituted aryl-fused benzodiazepines as dopamine D2 receptor antagonists for treating psychosis and bipolar disorders)

RN 660865-54-3 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-[(2S)-2-methoxypropyl]-4-methyl-1-piperazinyl]-2-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660865-55-4 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-[(2R)-2-methoxypropyl]-4-methyl-1-piperazinyl]-2-(1-methylethyl)- (CA INDEX NAME)

Absolute stereochemistry.



IT 660865-48-5P 660865-49-6P

RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of piperazine-substituted aryl-fused benzodiazepines as dopamine D2 receptor antagonists for treating psychosis and bipolar disorders)

10/523,147

RN 660865-48-5 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-(2-methoxypropyl)-1-piperazinyl]-2-(1-methylethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 660865-49-6 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-[(2R)-2-methoxypropyl]-1-piperazinyl]-2-(1-methylethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

IT 660863-54-7P 660863-55-8P 660863-57-0P
660863-58-1P 660863-60-5P 660863-61-6P
660863-62-7P 660863-63-8P 660863-64-9P
660863-65-0P 660863-66-1P 660863-68-3P
660863-69-4P 660863-70-7P 660863-71-8P
660863-76-3P 660863-77-4P 660863-78-5P
660863-79-6P 660863-80-9P 660863-81-0P
660863-83-2P 660863-84-3P 660863-86-5P
660863-90-1P 660863-91-2P 660863-92-3P
660863-93-4P 660863-97-8P 660863-98-9P
660864-03-9P 660864-04-0P 660864-07-3P
660864-11-9P 660864-15-3P 660864-17-5P
660864-19-7P 660864-21-1P 660864-22-2P


660864-24-4P 660864-26-6P 660864-31-3P
 660864-32-4P 660864-35-7P 660864-37-9P
 660864-40-4P 660864-43-7P 660864-45-9P
 660864-48-2P 660864-50-6P 660864-52-8P
 660864-53-9P 660864-54-0P 660864-59-5P
 660864-61-9P 660864-63-1P 660864-64-2P
 660864-67-5P 660864-68-6P 660864-69-7P
 660864-70-0P 660864-72-2P 660864-73-3P
 660864-74-4P 660864-78-8P 660864-80-2P
 660864-81-3P 660864-82-4P 660864-83-5P
 660864-84-6P 660864-86-8P 660864-89-1P
 660864-91-5P 660864-94-8P 660864-96-0P
 660864-98-2P 660865-04-3P 660865-09-8P
 660865-11-2P 660865-13-4P 660865-15-6P
 660865-18-9P 660865-20-3P 660865-22-5P
 660865-24-7P 660865-26-9P 660865-28-1P
 660865-29-2P 660865-31-6P 660865-33-8P
 660865-34-9P 660865-36-1P 660865-38-3P
 660865-40-7P 660865-42-9P 660865-44-1P
 660865-46-3P 660865-51-0P 660865-58-7P
 660865-59-8P 660865-60-1P 660865-62-3P
 660865-67-8P 660865-69-0P 660865-70-3P
 660865-72-5P 660865-74-7P 660865-75-8P
 660865-77-0P 660865-78-1P 660865-80-5P
 660865-84-9P 660865-87-2P 660865-89-4P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of piperazine-substituted aryl-fused benzodiazepines as dopamine D2 receptor antagonists for treating psychosis and bipolar disorders)

RN 660863-54-7 CAPLUS

CN 2-Piperazinemethanol, 4-(2-methyl-10H-thieno[2,3-b][1,5]benzodiazepin-4-yl)-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660863-55-8 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3R)-3-(methoxymethyl)-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 660863-57-0 CAPLUS

CN 2-Piperazineethanol, 4-(2-methyl-10H-thieno[2,3-b][1,5]benzodiazepin-4-yl)-, dihydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 660863-58-1 CAPLUS

CN 2-Piperazineethanol, 4-(2-methyl-10H-thieno[2,3-b][1,5]benzodiazepin-4-yl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 660863-60-5 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-(2-methoxyethyl)-1-piperazinyl]- (CA INDEX NAME)

10/523,147


Absolute stereochemistry.



RN 660863-61-6 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-(2-methoxyethyl)-1-piperazinyl]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 660863-62-7 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-3-(2-phenoxyethyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 660863-63-8 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-(2-ethoxyethyl)-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 660863-64-9 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3R)-3-(phenoxyethyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 660863-65-0 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-(2-methoxyethyl)-1-piperazinyl]-2-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660863-66-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-(3-methoxypropyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 660863-68-3 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-(4-methoxybutyl)-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 660863-69-4 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 8-fluoro-4-[(3S)-3-(2-methoxyethyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 660863-70-7 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 8-fluoro-4-[(3S)-3-(3-methoxypropyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 660863-71-8 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 8-fluoro-4-[(3S)-3-(2-methoxyethyl)-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 660863-76-3 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 7-fluoro-4-[(3S)-3-(3-methoxypropyl)-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 660863-77-4 CAPLUS

CN 2-Piperazineethanol, 4-(8-fluoro-2-methyl-10H-thieno[2,3-b][1,5]benzodiazepin-4-yl)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660863-78-5 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-(2-ethoxyethyl)-1-piperazinyl]-8-fluoro-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 660863-79-6 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-(2-ethoxyethyl)-1-piperazinyl]-7-fluoro-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 660863-80-9 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-ethyl-8-fluoro-4-[(3S)-3-(2-methoxyethyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 660863-81-0 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 8-fluoro-4-[(3S)-3-(2-methoxyethyl)-1-piperazinyl]-2-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660863-83-2 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 7,8-difluoro-4-[(3S)-3-(2-methoxyethyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 660863-84-3 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 7,8-difluoro-4-[(3S)-3-(2-methoxyethyl)-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 660863-86-5 CAPLUS

CN 2-Piperazineethanol, 4-(7,8-difluoro-2-methyl-10H-thieno[2,3-b][1,5]benzodiazepin-4-yl)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660863-90-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 8-chloro-4-[(3S)-3-(2-methoxyethyl)-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 660863-91-2 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 7-chloro-4-[(3S)-3-(2-methoxyethyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 660863-92-3 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 7-chloro-4-[(3S)-3-(3-methoxypropyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 660863-93-4 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 7-chloro-4-[(3S)-3-(2-methoxyethyl)-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 660863-97-8 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3R)-3-(ethoxymethyl)-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 660863-98-9 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3R)-4-methyl-3-[(2-propenyloxy)methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 660864-03-9 CAPLUS


CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 660864-04-0 CAPLUS
 CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-(3-methoxypropyl)-4-methyl-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 660864-07-3 CAPLUS
 CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-(2-ethoxyethyl)-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 660864-11-9 CAPLUS
 CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]-2-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660864-15-3 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-(4-methoxybutyl)-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 660864-17-5 CAPLUS


CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]-2-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 660864-19-7 CAPLUS
 CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-(3-methoxypropyl)-4-methyl-1-piperazinyl]-2-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 660864-21-1 CAPLUS
 CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 8-fluoro-4-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 660864-22-2 CAPLUS
 CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 8-fluoro-4-[(3S)-3-(3-methoxypropyl)-4-methyl-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 660864-24-4 CAPLUS

CN 2-Piperazineethanol, 4-(8-fluoro-2-methyl-10H-thieno[2,3-b][1,5]benzodiazepin-4-yl)-1-methyl-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660864-26-6 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 8-fluoro-4-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 660864-31-3 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 8-fluoro-4-[(3S)-3-(3-methoxypropyl)-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 660864-32-4 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 8-fluoro-4-[(3S)-3-(3-methoxypropyl)-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 660864-35-7 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 8-fluoro-4-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]-2-(trifluoromethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660864-37-9 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 8-fluoro-4-[(3S)-3-(3-methoxypropyl)-4-methyl-1-piperazinyl]-2-(trifluoromethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660864-40-4 CAPLUS


CN 2-Piperazineethanol, 4-(7,8-difluoro-2-methyl-10H-thieno[2,3-b][1,5]benzodiazepin-4-yl)-1-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 660864-43-7 CAPLUS
 CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 7,8-difluoro-4-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 660864-45-9 CAPLUS
 CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-ethyl-7,8-difluoro-4-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 660864-48-2 CAPLUS
 CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 7,8-difluoro-4-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 660864-50-6 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 7,8-difluoro-4-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]-2-(trifluoromethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660864-52-8 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 8-chloro-4-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 660864-53-9 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 7-chloro-4-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 660864-54-0 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 7-chloro-4-[(3S)-3-(3-methoxypropyl)-4-methyl-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 660864-59-5 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 7-chloro-4-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 660864-61-9 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 7-chloro-4-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]-2-(trifluoromethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660864-63-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 7-chloro-4-[(3S)-3-(3-methoxypropyl)-4-methyl-1-piperazinyl]-2-(trifluoromethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660864-64-2 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-3-[2-(phenylthio)ethyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 660864-67-5 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 8-fluoro-2-methyl-4-[(3S)-4-methyl-3-[2-(methylthio)ethyl]-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 660864-68-6 CAPLUS

CN 2-Piperazineethanol, 4-(2-methyl-4H-thiazolo[5,4-b][1,5]benzodiazepin-10-

yl)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660864-69-7 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-(2-methoxyethyl)-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 660864-70-0 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-(2-ethoxyethyl)-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 660864-72-2 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-ethyl-10-[(3S)-3-(2-methoxyethyl)-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 660864-73-3 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-(2-methoxyethyl)-1-piperazinyl]-2-propyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 660864-74-4 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-butyl-10-[(3S)-3-(2-methoxyethyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 660864-78-8 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-(2-methoxyethyl)-1-piperazinyl]-2-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660864-80-2 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-cyclopentyl-10-[(3S)-3-(2-methoxyethyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 660864-81-3 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine-2-methanol, 10-[(3S)-3-(2-methoxyethyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 660864-82-4 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine-2-carboxylic acid, 10-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 660864-83-5 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine-2-carboxylic acid,
10-[(3S)-3-(2-methoxyethyl)-1-piperazinyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 660864-84-6 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-(2-methoxyethyl)-1-piperazinyl]-2-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 660864-86-8 CAPLUS

10/523,147

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-(difluoromethyl)-10-[(3S)-3-(2-methoxyethyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 660864-89-1 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-(2-methoxyethyl)-1-piperazinyl]-2-(3,3,3-trifluoropropyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660864-91-5 CAPLUS

CN 2-Piperazineethanol, 1-methyl-4-(2-methyl-4H-thiazolo[5,4-b][1,5]benzodiazepin-10-yl)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660864-94-8 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-(2-ethoxyethyl)-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 660864-96-0 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-ethyl-10-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 660864-98-2 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]-2-propyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 660865-04-3 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]-2-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660865-09-8 CAPLUS


CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-cyclopentyl-10-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 660865-11-2 CAPLUS
 CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine-2-methanol, 10-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 660865-13-4 CAPLUS
 CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]-2-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 660865-15-6 CAPLUS
 CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-(difluoromethyl)-10-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 660865-18-9 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]-2-(3,3,3-trifluoropropyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660865-20-3 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-4-cyclopropyl-3-(2-methoxyethyl)-1-piperazinyl]-2-(1-methylethyl)- (CA INDEX NAME)

Absolute stereochemistry.




10/523,147

RN 660865-22-5 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-4-ethyl-3-(2-methoxyethyl)-1-piperazinyl]-2-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660865-24-7 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-(2-methoxyethyl)-4-propyl-1-piperazinyl]-2-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660865-26-9 CAPLUS

CN 1-Piperazineethanol, 2-(2-methoxyethyl)-4-[2-(1-methylethyl)-4H-thiazolo[5,4-b][1,5]benzodiazepin-10-yl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660865-28-1 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3,4-bis(2-methoxyethyl)-1-piperazinyl]-2-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660865-29-2 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-4-ethyl-3-(2-methoxyethyl)-1-piperazinyl]-2-(trifluoromethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660865-31-6 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-(2-methoxyethyl)-4-propyl-1-piperazinyl]-2-(trifluoromethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660865-33-8 CAPLUS

CN Piperazine, 1-(fluoroacetyl)-2-(2-methoxyethyl)-4-[2-(trifluoromethyl)-4H-thiazolo[5,4-b][1,5]benzodiazepin-10-yl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 660865-34-9 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-4-(2-fluoroethyl)-3-(2-methoxyethyl)-1-piperazinyl]-2-(trifluoromethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660865-36-1 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-4-(3-fluoropropyl)-3-(2-methoxyethyl)-1-piperazinyl]-2-(trifluoromethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660865-38-3 CAPLUS

CN 1-Piperazineethanol, 2-(2-methoxyethyl)-4-[2-(trifluoromethyl)-4H-thiazolo[5,4-b][1,5]benzodiazepin-10-yl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660865-40-7 CAPLUS

CN 1-Piperazinepropanol, 2-(2-methoxyethyl)-4-[2-(trifluoromethyl)-4H-thiazolo[5,4-b][1,5]benzodiazepin-10-yl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660865-42-9 CAPLUS

CN Ethanol, 2-[2-[(2S)-2-(2-methoxyethyl)-4-[2-(trifluoromethyl)-4H-thiazolo[5,4-b][1,5]benzodiazepin-10-yl]-1-piperazinyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 660865-44-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-(2-methoxypropyl)-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 660865-46-3 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-(2-methoxypropyl)-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 660865-51-0 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-(2-methoxypropyl)-4-methyl-1-piperazinyl]-2-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660865-58-7 CAPLUS

CN 2-Piperazineethanol, α,α -dimethyl-4-[2-(1-methylethyl)-4H-thiazolo[5,4-b][1,5]benzodiazepin-10-yl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660865-59-8 CAPLUS

CN 2-Piperazineethanol, $\alpha,\alpha,1$ -trimethyl-4-[2-(1-methylethyl)-4H-thiazolo[5,4-b][1,5]benzodiazepin-10-yl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660865-60-1 CAPLUS

CN 2-Piperazineethanol, α, α -dimethyl-4-(2-methyl-10H-thieno[2,3-b][1,5]benzodiazepin-4-yl)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660865-62-3 CAPLUS

CN 2-Piperazineethanol, $\alpha, \alpha, 1$ -trimethyl-4-(2-methyl-10H-thieno[2,3-b][1,5]benzodiazepin-4-yl)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660865-67-8 CAPLUS

CN 2-Piperazineethanol, α ,1-dimethyl-4-(2-methyl-10H-thieno[2,3-b][1,5]benzodiazepin-4-yl)-, (α S,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660865-69-0 CAPLUS

CN 2-Piperazineethanol, α ,1-dimethyl-4-(2-methyl-10H-thieno[2,3-b][1,5]benzodiazepin-4-yl)-, (α R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660865-70-3 CAPLUS

CN 6H-[1]Benzothieno[2,3-b][1,5]benzodiazepine, 12-[(3S)-3-(2-methoxyethyl)-1-piperazinyl]-9-(trifluoromethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660865-72-5 CAPLUS

CN 6H-[1]Benzothieno[2,3-b][1,5]benzodiazepine, 12-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]-9-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.




10/523,147

RN 660865-74-7 CAPLUS

CN 6H-[1]Benzo[thieno[2,3-b][1,5]benzodiazepine, 12-[(3S)-3-(2-methoxyethyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 660865-75-8 CAPLUS

CN 6H-[1]Benzo[thieno[2,3-b][1,5]benzodiazepine, 12-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 660865-77-0 CAPLUS

CN 6H-[1]Benzo[thieno[2,3-b][1,5]benzodiazepine, 9-fluoro-12-[(3S)-3-(2-methoxyethyl)-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.




10/523,147

RN 660865-78-1 CAPLUS

CN 6H-[1]Benzothieno[2,3-b][1,5]benzodiazepine, 9-fluoro-12-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 660865-80-5 CAPLUS

CN 6H-[1]Benzothieno[2,3-b][1,5]benzodiazepine, 8-fluoro-12-[(3S)-3-(2-methoxyethyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 660865-84-9 CAPLUS

CN 6H-[1]Benzothieno[2,3-b][1,5]benzodiazepine, 8-fluoro-12-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 660865-87-2 CAPLUS

CN 6H-[1]Benzothieno[2,3-b][1,5]benzodiazepine, 8,9-difluoro-12-[(3S)-3-(2-methoxyethyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 660865-89-4 CAPLUS

CN 6H-[1]Benzothieno[2,3-b][1,5]benzodiazepine, 8,9-difluoro-12-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 660863-56-9P 660863-59-2P 660863-67-2P

660863-72-9P 660863-74-1P 660863-75-2P

660863-85-4P 660863-87-6P 660863-88-7P
 660863-94-5P 660863-95-6P 660863-96-7P
 660863-99-0P 660864-00-6P 660864-01-7P
 660864-02-8P 660864-05-1P 660864-06-2P
 660864-08-4P 660864-09-5P 660864-12-0P
 660864-13-1P 660864-14-2P 660864-16-4P
 660864-18-6P 660864-20-0P 660864-23-3P
 660864-25-5P 660864-27-7P 660864-28-8P
 660864-29-9P 660864-30-2P 660864-33-5P
 660864-34-6P 660864-36-8P 660864-38-0P
 660864-39-1P 660864-41-5P 660864-42-6P
 660864-44-8P 660864-46-0P 660864-49-3P
 660864-51-7P 660864-55-1P 660864-57-3P
 660864-60-8P 660864-62-0P 660864-65-3P
 660864-66-4P 660864-75-5P 660864-76-6P
 660864-77-7P 660864-79-9P 660864-85-7P
 660864-87-9P 660864-88-0P 660864-90-4P
 660864-92-6P 660864-93-7P 660864-95-9P
 660864-97-1P 660864-99-3P 660865-00-9P
 660865-02-1P 660865-03-2P 660865-05-4P
 660865-06-5P 660865-07-6P 660865-08-7P
 660865-10-1P 660865-12-3P 660865-14-5P
 660865-16-7P 660865-17-8P 660865-19-0P
 660865-21-4P 660865-23-6P 660865-25-8P
 660865-27-0P 660865-30-5P 660865-32-7P
 660865-35-0P 660865-37-2P 660865-39-4P
 660865-41-8P 660865-43-0P 660865-45-2P
 660865-52-1P 660865-53-2P 660865-56-5P
 660865-57-6P 660865-61-2P 660865-64-5P
 660865-65-6P 660865-66-7P 660865-68-9P
 660865-71-4P 660865-73-6P 660865-76-9P
 660865-79-2P 660865-81-6P 660865-83-8P
 660865-85-0P 660865-86-1P 660865-88-3P
 660865-91-8P 660865-92-9P 660865-93-0P
 660865-94-1P 660865-95-2P 660865-96-3P
 660865-97-4P 660865-98-5P 660865-99-6P
 660866-00-2P 660866-01-3P 660866-02-4P
 660866-03-5P 660866-04-6P 660866-05-7P
 660866-06-8P 660866-07-9P 660866-08-0P
 660866-09-1P 660866-10-4P 660866-11-5P
 660866-12-6P 660866-13-7P 660866-14-8P
 660866-15-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(drug candidate; preparation of piperazine-substituted aryl-fused
 benzodiazepines as dopamine D2 receptor antagonists for treating
 psychosis and bipolar disorders)

RN 660863-56-9 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3R)-3-[[2-methyl-2-
 propenyl]oxy]methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 660863-59-2 CAPLUS

CN 2-Piperazineethanol, 4-(2-methyl-10H-thieno[2,3-b][1,5]benzodiazepin-4-yl)-, dihydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 660863-67-2 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-(3-methoxypropyl)-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 660863-72-9 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 8-fluoro-4-[(3S)-3-(2-methoxyethyl)-1-piperazinyl]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 660863-74-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 8-fluoro-4-[(3S)-3-(3-methoxypropyl)-1-piperazinyl]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 660863-75-2 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 7-fluoro-4-[(3S)-3-(2-methoxyethyl)-1-piperazinyl]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 660863-85-4 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 7,8-difluoro-4-[(3S)-3-(2-methoxyethyl)-1-piperazinyl]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 660863-87-6 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-(2-ethoxyethyl)-1-piperazinyl]-7,8-difluoro-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 660863-88-7 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-ethyl-7,8-difluoro-4-[(3S)-3-(2-methoxyethyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 660863-94-5 CAPLUS

CN 2-Piperazineethanol, 4-(7-chloro-2-methyl-10H-thieno[2,3-b][1,5]benzodiazepin-4-yl)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660863-95-6 CAPLUS

CN 2-Piperazineethanol, 1-methyl-4-(2-methyl-10H-thieno[2,3-b][1,5]benzodiazepin-4-yl)-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660863-96-7 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3R)-3-(methoxymethyl)-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 660863-99-0 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3R)-4-methyl-3-(propoxymethyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 660864-00-6 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3R)-4-methyl-3-[(2-methyl-2-propenyl)oxy)methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 660864-01-7 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3R)-4-methyl-3-(phenoxymethyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 660864-02-8 CAPLUS

CN 2-Piperazineethanol, 1-methyl-4-(2-methyl-10H-thieno[2,3-b][1,5]benzodiazepin-4-yl)-, dihydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 660864-05-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 660864-06-2 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-(2-ethoxyethyl)-4-methyl-1-piperazinyl]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 660864-08-4 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-4-methyl-3-(2-phenoxyethyl)-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 660864-09-5 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3R)-4-methyl-3-[(phenylmethoxy)methyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 660864-12-0 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]-2-(1-methylethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 660864-13-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-(3-methoxypropyl)-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 660864-14-2 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-(3-methoxypropyl)-4-methyl-1-piperazinyl]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 660864-16-4 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-(4-methoxybutyl)-4-methyl-1-piperazinyl]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 660864-18-6 CAPLUS
 CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]-2-(trifluoromethyl)-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 660864-17-5
 CMF C20 H23 F3 N4 O S

Absolute stereochemistry.




CM 2

CRN 110-16-7
 CMF C4 H4 O4

Double bond geometry as shown.

10/523,147




RN 660864-20-0 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-(3-methoxypropyl)-4-methyl-1-piperazinyl]-2-(trifluoromethyl)-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 660864-19-7
CMF C21 H25 F3 N4 O S


Absolute stereochemistry.



CM 2


CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 660864-23-3 CAPLUS
CN 2-Piperazineethanol, 4-(8-fluoro-2-methyl-10H-thieno[2,3-b][1,5]benzodiazepin-4-yl)-1-methyl-, dihydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 660864-25-5 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 8-fluoro-4-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 660864-27-7 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-ethyl-8-fluoro-4-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 660864-28-8 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-(2-ethoxyethyl)-4-methyl-1-piperazinyl]-8-fluoro-2-methyl-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

RN 660864-29-9 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 8-fluoro-4-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]-2-(1-methylethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 660864-30-2 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 8-fluoro-4-[(3S)-3-(3-methoxypropyl)-4-methyl-1-piperazinyl]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 660864-33-5 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 7-fluoro-4-[(3S)-3-(3-methoxypropyl)-4-methyl-1-piperazinyl]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 660864-34-6 CAPLUS
 CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 8-fluoro-4-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]-2-(trifluoromethyl)-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 660864-36-8 CAPLUS
 CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 8-fluoro-4-[(3S)-3-(3-methoxypropyl)-4-methyl-1-piperazinyl]-2-(trifluoromethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 660864-38-0 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 7-fluoro-4-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]-2-methyl-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

RN 660864-39-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-(2-ethoxyethyl)-4-methyl-1-piperazinyl]-7-fluoro-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/523,147



● 2 HCl

RN 660864-41-5 CAPLUS
 CN 2-Piperazineethanol, 4-(7,8-difluoro-2-methyl-10H-thieno[2,3-b][1,5]benzodiazepin-4-yl)-1-methyl-, dihydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 660864-42-6 CAPLUS
 CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 7,8-difluoro-4-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 660864-44-8 CAPLUS
 CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-(2-ethoxyethyl)-4-methyl-1-piperazinyl]-7,8-difluoro-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl


RN 660864-46-0 CAPLUS
 CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-ethyl-7,8-difluoro-4-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]-, butanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 660864-45-9

CMF C21 H26 F2 N4 O S

Absolute stereochemistry.



CM 2

CRN 110-15-6


CMF C4 H6 O4



RN 660864-49-3 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 7,8-difluoro-4-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]-2-(trifluoromethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 660864-51-7 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 8-chloro-4-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/523,147



● 2 HCl

RN 660864-55-1 CAPLUS
CN 2-Piperazineethanol, 4-(7-chloro-2-methyl-10H-thieno[2,3-b][1,5]benzodiazepin-4-yl)-1-methyl-, dihydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 660864-57-3 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 7-chloro-4-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 660864-60-8 CAPLUS
 CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 7-chloro-4-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]-2-(trifluoromethyl)-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 660864-62-0 CAPLUS
 CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 7-chloro-4-[(3S)-3-(3-methoxypropyl)-4-methyl-1-piperazinyl]-2-(trifluoromethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 660864-65-3 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-4-methyl-3-[2-(phenylthio)ethyl]-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 660864-66-4 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 8-fluoro-2-methyl-4-[(3S)-4-methyl-3-[2-(methylthio)ethyl]-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 660864-75-5 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-butyl-10-[(3S)-3-(2-methoxyethyl)-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 660864-76-6 CAPLUS

CN 2-Piperazineethanol, 4-[2-(1-methylethyl)-4H-thiazolo[5,4-b][1,5]benzodiazepin-10-yl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660864-77-7 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-(2-methoxyethyl)-1-piperazinyl]-2-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660864-79-9 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-(3-methoxypropyl)-1-piperazinyl]-2-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660864-85-7 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-(2-methoxyethyl)-1-piperazinyl]-2-(trifluoromethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 660864-87-9 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-(difluoromethyl)-10-[(3S)-3-(2-methoxyethyl)-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 660864-88-0 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-(2-methoxyethyl)-1-piperazinyl]-2-(3,3,3-trifluoropropyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 660864-90-4 CAPLUS

CN 2-Piperazineethanol, 1-methyl-4-(2-methyl-4H-thiazolo[5,4-b][1,5]benzodiazepin-10-yl)-, dihydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 660864-92-6 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 660864-93-7 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-(2-ethoxyethyl)-4-methyl-1-piperazinyl]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 660864-95-9 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-ethyl-10-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 660864-97-1 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]-2-propyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 660864-99-3 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-butyl-10-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 660865-00-9 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-butyl-10-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 660865-02-1 CAPLUS

CN 2-Piperazineethanol, 1-methyl-4-[2-(1-methylethyl)-4H-thiazolo[5,4-b][1,5]benzodiazepin-10-yl]-, dihydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●2 HCl

RN 660865-03-2 CAPLUS
 CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]-2-(1-methylethyl)-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●2 HCl

RN 660865-05-4 CAPLUS
 CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-(2-ethoxyethyl)-4-methyl-1-piperazinyl]-2-(1-methylethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 660865-06-5 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-(3-methoxypropyl)-4-methyl-1-piperazinyl]-2-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660865-07-6 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-(3-methoxypropyl)-4-methyl-1-piperazinyl]-2-(1-methylethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 660865-08-7 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-cyclopentyl-10-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 660865-10-1 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine-2-methanol, 10-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 660865-12-3 CAPLUS
 CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine-2-carboxylic acid,
 10-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]-, ethyl ester,
 dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 660865-14-5 CAPLUS
 CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]-2-(trifluoromethyl)-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●2 HCl

RN 660865-16-7 CAPLUS
 CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-(difluoromethyl)-10-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●2 HCl

RN 660865-17-8 CAPLUS
 CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]-2-(3,3,3-trifluoropropyl)-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 660865-19-0 CAPLUS
 CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-4-cyclopropyl-3-(2-methoxyethyl)-1-piperazinyl]-2-(1-methylethyl)-, dihydrochloride (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 660865-21-4 CAPLUS
 CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-4-ethyl-3-(2-methoxyethyl)-1-piperazinyl]-2-(1-methylethyl)-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 660865-23-6 CAPLUS
CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-(2-methoxyethyl)-4-propyl-1-piperazinyl]-2-(1-methylethyl)-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 660865-25-8 CAPLUS
CN 1-Piperazineethanol, 2-(2-methoxyethyl)-4-[2-(1-methylethyl)-4H-thiazolo[5,4-b][1,5]benzodiazepin-10-yl]-, dihydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 660865-27-0 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3,4-bis(2-methoxyethyl)-1-piperazinyl]-2-(1-methylethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 660865-30-5 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-4-ethyl-3-(2-methoxyethyl)-1-piperazinyl]-2-(trifluoromethyl)-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 660865-32-7 CAPLUS
CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-(2-methoxyethyl)-4-propyl-1-piperazinyl]-2-(trifluoromethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 660865-35-0 CAPLUS
CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-4-(2-fluoroethyl)-3-(2-methoxyethyl)-1-piperazinyl]-2-(trifluoromethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/523,147




● 2 HCl

RN 660865-37-2 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-4-(3-fluoropropyl)-3-(2-methoxyethyl)-1-piperazinyl]-2-(trifluoromethyl)-, dihydrochloride (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 660865-39-4 CAPLUS

CN 1-Piperazineethanol, 2-(2-methoxyethyl)-4-[2-(trifluoromethyl)-4H-thiazolo[5,4-b][1,5]benzodiazepin-10-yl]-, dihydrochloride, (2S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 660865-41-8 CAPLUS
 CN 1-Piperazinepropanol, 2-(2-methoxyethyl)-4-[2-(trifluoromethyl)-4H-thiazolo[5,4-b][1,5]benzodiazepin-10-yl]-, dihydrochloride, (2S)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 660865-43-0 CAPLUS
 CN Ethanol, 2-[2-[(2S)-2-(2-methoxyethyl)-4-[2-(trifluoromethyl)-4H-thiazolo[5,4-b][1,5]benzodiazepin-10-yl]-1-piperazinyl]ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/523,147




●2 HCl

RN 660865-45-2 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-(2-methoxypropyl)-4-methyl-1-piperazinyl]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 660865-52-1 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-[(2S)-2-methoxypropyl]-4-methyl-1-piperazinyl]-2-(1-methylethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 660865-53-2 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-[(2R)-2-methoxypropyl]-4-methyl-1-piperazinyl]-2-(1-methylethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 660865-56-5 CAPLUS

CN 2-Piperazineethanol, α,α -dimethyl-4-[2-(1-methylethyl)-4H-thiazolo[5,4-b][1,5]benzodiazepin-10-yl]-, dihydrochloride, (2S)- (9CI) (CA INDEX NAME)

10/523,147

Absolute stereochemistry.




● 2 HCl

RN 660865-57-6 CAPLUS

CN 2-Piperazineethanol, $\alpha,\alpha,1$ -trimethyl-4-[2-(1-methylethyl)-4H-thiazolo[5,4-b][1,5]benzodiazepin-10-yl]-, dihydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 660865-61-2 CAPLUS

CN 2-Piperazineethanol, $\alpha,\alpha,1$ -trimethyl-4-(2-methyl-10H-thieno[2,3-b][1,5]benzodiazepin-4-yl)-, dihydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 660865-64-5 CAPLUS

CN 2-Piperazineethanol, α -methyl-4-(2-methyl-10H-thieno[2,3-b][1,5]benzodiazepin-4-yl)-, dihydrochloride, (α S,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 660865-65-6 CAPLUS

CN 2-Piperazineethanol, α -methyl-4-(2-methyl-10H-thieno[2,3-b][1,5]benzodiazepin-4-yl)-, dihydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 660865-66-7 CAPLUS

CN 2-Piperazineethanol, α ,1-dimethyl-4-(2-methyl-10H-thieno[2,3-b][1,5]benzodiazepin-4-yl)-, dihydrochloride, (α S,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 660865-68-9 CAPLUS

CN 2-Piperazineethanol, α ,1-dimethyl-4-(2-methyl-10H-thieno[2,3-b][1,5]benzodiazepin-4-yl)-, dihydrochloride, (α R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 660865-71-4 CAPLUS

CN 6H-[1]Benzothieno[2,3-b][1,5]benzodiazepine, 12-[(3S)-3-(2-methoxyethyl)-1-piperazinyl]-9-(trifluoromethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 660865-73-6 CAPLUS

CN 6H-[1]Benzothieno[2,3-b][1,5]benzodiazepine, 12-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]-9-(trifluoromethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 660865-76-9 CAPLUS

CN 6H-[1]Benzothieno[2,3-b][1,5]benzodiazepine, 12-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 660865-79-2 CAPLUS

CN 6H-[1]Benzothieno[2,3-b][1,5]benzodiazepine, 9-fluoro-12-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/523,147




● 2 HCl

RN 660865-81-6 CAPLUS

CN 6H-[1]Benzothieno[2,3-b][1,5]benzodiazepine, 8-fluoro-12-[(3S)-3-(3-methoxypropyl)-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 660865-83-8 CAPLUS

CN 6H-[1]Benzothieno[2,3-b][1,5]benzodiazepine, 8-fluoro-12-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/523,147




● 2 HCl

RN 660865-85-0 CAPLUS

CN 6H-[1]Benzothieno[2,3-b][1,5]benzodiazepine, 8-fluoro-12-[(3S)-3-(3-methoxypropyl)-4-methyl-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 660865-86-1 CAPLUS

CN 6H-[1]Benzothieno[2,3-b][1,5]benzodiazepine, 8-fluoro-12-[(3S)-3-(3-methoxypropyl)-4-methyl-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 660865-88-3 CAPLUS

CN 6H-[1]Benzothieno[2,3-b][1,5]benzodiazepine, 8,9-difluoro-12-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 660865-91-8 CAPLUS


CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-chloro-4-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 660865-92-9 CAPLUS
 CN 2-Piperazineethanol, 4-(2-methyl-10H-thieno[2,3-b][1,5]benzodiazepin-4-yl)-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 660865-93-0 CAPLUS
 CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-(2-methoxyethyl)-1-piperazinyl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 660865-94-1 CAPLUS
 CN 2-Piperazineethanol, 1-methyl-4-(2-methyl-10H-thieno[2,3-b][1,5]benzodiazepin-4-yl)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660865-95-2 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 660865-96-3 CAPLUS


CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-4-methyl-3-(2-phenoxyethyl)-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 660865-97-4 CAPLUS
 CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-ethyl-8-fluoro-4-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 660865-98-5 CAPLUS
 CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-(2-ethoxyethyl)-4-methyl-1-piperazinyl]-8-fluoro-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 660865-99-6 CAPLUS
 CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 8-fluoro-4-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]-2-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660866-00-2 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 7-fluoro-4-[(3S)-3-(3-methoxypropyl)-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 660866-01-3 CAPLUS


CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 7-fluoro-4-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 660866-02-4 CAPLUS
 CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-(2-ethoxyethyl)-4-methyl-1-piperazinyl]-7-fluoro-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 660866-03-5 CAPLUS
 CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-(2-ethoxyethyl)-4-methyl-1-piperazinyl]-7,8-difluoro-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 660866-04-6 CAPLUS
 CN 2-Piperazineethanol, 4-(7-chloro-2-methyl-10H-thieno[2,3-b][1,5]benzodiazepin-4-yl)-1-methyl-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660866-05-7 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-4-methyl-3-[2-(phenylthio)ethyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 660866-06-8 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[(2S)-2-methoxypropyl]-1-piperazinyl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 660866-07-9 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[(2R)-2-methoxypropyl]-1-

10/523,147

piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 660866-08-0 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[(2S)-2-methoxypropyl]-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 660866-09-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[(2R)-2-methoxypropyl]-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 660866-10-4 CAPLUS

CN 2-Piperazineethanol, α -methyl-4-(2-methyl-10H-thieno[2,3-b][1,5]benzodiazepin-4-yl)-, (α R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660866-11-5 CAPLUS

CN 2-Piperazineethanol, α -methyl-4-(2-methyl-10H-thieno[2,3-b][1,5]benzodiazepin-4-yl)-, (α S,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660866-12-6 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-(2-methoxyethyl)-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 660866-13-7 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-(2-ethoxyethyl)-4-methyl-1-piperazinyl]-2-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660866-14-8 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-[(2S)-2-methoxypropyl]-1-piperazinyl]-2-(1-methylethyl)- (CA INDEX NAME)

Absolute stereochemistry.




10/523,147

RN 660866-15-9 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-[(2R)-2-methoxypropyl]-1-piperazinyl]-2-(1-methylethyl)- (CA INDEX NAME)

Absolute stereochemistry.



IT 660864-10-8 660864-47-1 660864-56-2

660864-58-4 660865-01-0


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of piperazine-substituted aryl-fused benzodiazepines as dopamine D2 receptor antagonists for treating psychosis and bipolar disorders)

RN 660864-10-8 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3R)-3-[(phenylmethoxy)methyl]-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 660864-47-1 CAPLUS


CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-ethyl-7,8-difluoro-4-[(3S)-3-(2-methoxyethyl)-1-piperazinyl]-, butanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 660863-88-7

CMF C20 H24 F2 N4 O S


Absolute stereochemistry.



CM 2

CRN 110-15-6


CMF C4 H6 O4



RN 660864-56-2 CAPLUS

CN 2-Piperazineethanol, 4-(7-chloro-2-methyl-10H-thieno[2,3-b][1,5]benzodiazepin-4-yl)-, dihydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 660864-58-4 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 7-chloro-4-[(3S)-3-(2-methoxyethyl)-1-piperazinyl]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/523,147




● 2 HCl

RN 660865-01-0 CAPLUS

CN 2-Piperazineethanol, 1-methyl-4-[2-(1-methylethyl)-4H-thiazolo[5,4-b][1,5]benzodiazepin-10-yl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:796711 CAPLUS

DOCUMENT NUMBER: 139:307804

TITLE: Preparation of 10-piperazinyl-4H-3-thia-4,9-diazabenzofluzulenes and aryl-fused benzodiazepine analogs as dopamine receptor antagonists for the treatment of psychotic disorders

INVENTOR(S): Aicher, Thomas Daniel; Chen, Zhaoen; Chen, Ying; Faul, Margaret Mary; Krushinski, Joseph Herman, Jr.; Le Huerou, Yvan; Pineiro-Nunez, Marta Maria; Rocco, Vincent Patrick; Ruley, Kevin Michael; Schaus, John Mehnert; Thompson, Dennis Charles; Tupper, David Edward

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 293 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003082877	A1	20031009	WO 2003-US6708	20030317
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2479932	A1	20031009	CA 2003-2479932	20030317
AU 2003217936	A1	20031013	AU 2003-217936	20030317
EP 1492794	A1	20050105	EP 2003-713911	20030317
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005533009	T	20051104	JP 2003-580342	20030317
US 2005203296	A1	20050915	US 2004-505805	20040826
US 7214673	B2	20070508		
PRIORITY APPLN. INFO.:			US 2002-368670P	P 20020328
			WO 2003-US6708	W 20030317

OTHER SOURCE(S): MARPAT 139:307804

GI



AB Title compds. I [wherein A = optionally benzo-fused 5- or 6-membered (hetero)aromatic ring; Alk = (un)substituted alkylene; Ar = (un)substituted Ph, naphthyl, or heteroaryl; R1 = H or (un)substituted alkyl; R2 = H, (fluoro)alkyl, halo, OR4, SR4, NO2, CN, COR4, CONR5R6, SO2NR5R6, NR5R6, NR5COR4, NR5SO2R4, or (un)substituted Ph; R4 = H, (fluoro)alkyl, PhCH2, or (un)substituted Ph; R5 and R6 = independently H, alkyl, or (un)substituted Ph; Z = 1-2 substituents independently selected from H, halo, (fluoro)alkyl, OR7, SR7, NO2, CN, COR7, CONR8R9, SO2NR8R9, NR8SO2R7, NR8R9, or (un)substituted Ph; R7 = H, (fluoro)alkyl, PhCH2, or (un)substituted Ph; R8 and R9 = independently H, alkyl, or (un)substituted Ph; or salts, solvates, and crystal forms thereof] were prepared as antagonists of the dopamine D2 receptor. For example, reaction of 2-methyl-4H-3-thia-4,9-diazabenzofluzulen-10-ylamine•HCl with 2-(S)-phenethylpiperazine in the presence of DMSO in toluene gave II (65%). Thirty-eight compds. of the invention, including II, were assayed and showed moderate to high affinity for the D2 receptor with Ki values in ranging from <10 nM to 100 nM. Thus, I and their pharmaceutical formulations are useful as antipsychotics for the treatment of schizophrenia and bipolar disorders (no data).

IT 612506-41-9P 612506-44-2P


RL: PAC (Pharmacological activity); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(antipsychotic; preparation of aryl-fused benzodiazepine D2 receptor antagonists as antipsychotics)

RN 612506-41-9 CAPLUS

CN 2-Piperazineethanol, 4-(2-methyl-10H-thieno[2,3-b][1,5]benzodiazepin-4-yl)- α -phenyl-, (α S,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 612506-44-2 CAPLUS

CN 2-Piperazineethanol, 4-[2-(1-methylethyl)-10H-thieno[2,3-b][1,5]benzodiazepin-4-yl]-α-phenyl-, (αS,2S)- (CA INDEX NAME)

Absolute stereochemistry.




IT 612506-42-0P 612506-43-1P

RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antipsychotic; preparation of aryl-fused benzodiazepine D2 receptor antagonists as antipsychotics)

RN 612506-42-0 CAPLUS


CN 2-Piperazineethanol, 1-methyl-4-(2-methyl-10H-thieno[2,3-b][1,5]benzodiazepin-4-yl)-α-phenyl-, (αS,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 612506-43-1 CAPLUS
 CN 2-Piperazineethanol, 4-[2-(1-methylethyl)-10H-thieno[2,3-b][1,5]benzodiazepin-4-yl]- α -phenyl-, (α R,2S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 612502-50-8P 612502-80-4P 612504-51-5P
 612504-52-6P 612504-53-7P 612504-57-1P
 612504-58-2P 612504-59-3P 612504-63-9P
 612504-82-2P 612504-87-7P 612504-91-3P
 612504-92-4P 612505-02-9P 612505-15-4P
 612505-16-5P 612505-17-6P 612505-19-8P
 612505-20-1P 612505-21-2P 612505-22-3P
 612505-23-4P 612505-24-5P 612505-37-0P
 612505-39-2P 612505-46-1P 612505-48-3P
 612505-50-7P 612505-54-1P 612505-55-2P
 612505-56-3P 612505-57-4P 612505-64-3P
 612505-66-5P 612505-68-7P 612505-70-1P
 612505-72-3P 612505-74-5P 612505-76-7P
 612505-79-0P 612505-81-4P 612505-83-6P
 612505-85-8P 612505-87-0P 612505-89-2P
 612505-91-6P 612505-93-8P 612512-57-9P
 612512-58-0P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(antipsychotic; preparation of aryl-fused benzodiazepine D2 receptor antagonists as antipsychotics)

RN 612502-50-8 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-3-(2-phenylethyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612502-80-4 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-4-methyl-3-(2-phenylethyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612504-51-5 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[2-(3-chlorophenyl)ethyl]-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612504-52-6 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[2-(4-chlorophenyl)ethyl]-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612504-53-7 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[2-(2-chlorophenyl)ethyl]-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612504-57-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-3-[2-[4-(trifluoromethyl)phenyl]ethyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612504-58-2 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-3-[2-[2-(trifluoromethyl)phenyl]ethyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612504-59-3 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-3-[2-[3-(trifluoromethyl)phenyl]ethyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612504-63-9 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[2-(2,4-difluorophenyl)ethyl]-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612504-82-2 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-3-[2-(1-naphthalenyl)ethyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612504-87-7 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-4-methyl-3-[2-(2-naphthalenyl)ethyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612504-91-3 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[2-(3-furanyl)ethyl]-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612504-92-4 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-(2-(3-furanyl)ethyl)-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612505-02-9 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-(1,1-dimethylethyl)-4-[(3S)-3-(2-phenylethyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612505-15-4 CAPLUS


CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-methyl-10-[(3S)-3-(phenylmethyl)-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 612505-16-5 CAPLUS
 CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-[(2-methoxyphenyl)methyl]-1-piperazinyl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 612505-17-6 CAPLUS
 CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-[2-(4-methoxyphenyl)ethyl]-1-piperazinyl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 612505-19-8 CAPLUS
 CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-[2-(4-fluorophenyl)ethyl]-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612505-20-1 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-[2-(3-fluorophenyl)ethyl]-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612505-21-2 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-(1-methylethyl)-10-[(3S)-3-(2-phenylethyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612505-22-3 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-[2-(4-methoxyphenyl)ethyl]-1-piperazinyl]-2-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 612505-23-4 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-[2-(3-fluorophenyl)ethyl]-1-piperazinyl]-2-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 612505-24-5 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-[2-(4-fluorophenyl)ethyl]-1-piperazinyl]-2-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 612505-37-0 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-butyl-10-[(3S)-3-(2-phenylethyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612505-39-2 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-butyl-10-[(3S)-4-methyl-3-(2-phenylethyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612505-46-1 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-cyclopentyl-10-[(3S)-3-(phenylmethyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612505-48-3 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-cyclopentyl-10-[(3S)-3-[2-(3-methoxyphenyl)ethyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612505-50-7 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-cyclopentyl-10-[(3S)-3-[2-(4-methoxyphenyl)ethyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612505-54-1 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-ethyl-10-[(3S)-3-[2-(4-methoxyphenyl)ethyl]-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 612505-55-2 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-ethyl-10-[(3S)-3-[2-(4-

fluorophenyl)ethyl]-1-piperaziny]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612505-56-3 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-ethyl-10-[(3S)-3-[2-(3-fluorophenyl)ethyl]-1-piperaziny]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612505-57-4 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-ethyl-10-[(3S)-3-[2-(3-methoxyphenyl)ethyl]-1-piperaziny]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612505-64-3 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-[2-(3-trifluoromethyl)ethyl]-1-piperaziny]-2-(trifluoromethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 612505-66-5 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-[2-(4-fluorophenyl)ethyl]-1-piperazinyl]-2-(trifluoromethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 612505-68-7 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-[2-(3-methoxyphenyl)ethyl]-1-piperazinyl]-2-(trifluoromethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 612505-70-1 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-[2-(4-methoxyphenyl)ethyl]-1-piperazinyl]-2-(trifluoromethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 612505-72-3 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-[2-(3-fluorophenyl)ethyl]-4-methyl-1-piperazinyl]-2-(trifluoromethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 612505-74-5 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-[2-(4-methoxyphenyl)ethyl]-4-methyl-1-piperazinyl]-2-(trifluoromethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 612505-76-7 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-[2-(4-fluorophenyl)ethyl]-4-methyl-1-piperazinyl]-2-(trifluoromethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 612505-79-0 CAPLUS

CN 6H-[1]Benzothieno[2,3-b][1,5]benzodiazepine, 8-fluoro-12-[(3S)-3-(2-phenylethyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612505-81-4 CAPLUS

CN 6H-[1]Benzothieno[2,3-b][1,5]benzodiazepine, 8-fluoro-12-[(3S)-3-[2-(4-methoxyphenyl)ethyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612505-83-6 CAPLUS

CN 6H-[1]Benzothieno[2,3-b][1,5]benzodiazepine, 8-fluoro-12-[(3S)-3-[2-(3-methoxyphenyl)ethyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612505-85-8 CAPLUS

CN 6H-[1]Benzothieno[2,3-b][1,5]benzodiazepine, 8-fluoro-12-[(3S)-3-[2-(3-fluorophenyl)ethyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612505-87-0 CAPLUS

CN 6H-[1]Benzothieno[2,3-b][1,5]benzodiazepine, 8-fluoro-12-[(3S)-3-[2-(4-fluorophenyl)ethyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612505-89-2 CAPLUS

CN 6H-[1]Benzothieno[2,3-b][1,5]benzodiazepine, 8-fluoro-12-[(3S)-3-[2-(4-methoxyphenyl)ethyl]-4-methyl-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612505-91-6 CAPLUS

CN 6H-[1]Benzothieno[2,3-b][1,5]benzodiazepine, 8-fluoro-12-[(3S)-3-[2-(3-methoxyphenyl)ethyl]-4-methyl-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612505-93-8 CAPLUS

CN 6H-[1]Benzothieno[2,3-b][1,5]benzodiazepine, 8-fluoro-12-[(3S)-3-[2-(3-fluorophenyl)ethyl]-4-methyl-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612512-57-9 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-(1-methylethyl)-10-[(3S)-3-(phenylmethyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612512-58-0 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-[2-(3-methoxyphenyl)ethyl]-4-methyl-1-piperazinyl]-2-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.



IT 612502-51-9P 612502-52-0P 612502-53-1P
 612502-54-2P 612502-55-3P 612502-56-4P
 612502-57-5P 612502-58-6P 612502-59-7P
 612502-60-0P 612502-61-1P 612502-62-2P
 612502-63-3P 612502-64-4P 612502-65-5P
 612502-66-6P 612502-67-7P 612502-68-8P
 612502-69-9P 612502-70-2P 612502-71-3P
 612502-72-4P 612502-73-5P 612502-74-6P
 612502-75-7P 612502-76-8P 612502-77-9P
 612502-78-0P 612502-79-1P 612502-81-5P
 612502-82-6P 612502-83-7P 612502-84-8P
 612502-85-9P 612502-87-1P 612502-88-2P
 612502-89-3P 612502-90-6P 612502-91-7P
 612502-92-8P 612502-93-9P 612502-94-0P
 612502-95-1P 612502-96-2P 612502-97-3P
 612502-98-4P 612502-99-5P 612503-00-1P
 612503-01-2P 612503-02-3P 612503-03-4P
 612503-04-5P 612503-05-6P 612503-06-7P
 612503-07-8P 612503-15-8P 612503-16-9P
 612503-42-1P 612503-43-2P 612503-44-3P
 612503-45-4P 612503-46-5P 612503-47-6P
 612503-48-7P 612503-49-8P 612503-50-1P
 612503-51-2P 612503-52-3P 612503-53-4P
 612503-54-5P 612503-55-6P 612503-56-7P

612503-57-8P 612503-60-3P, (S)-2-Methyl-10-[3-(4-phenylbutyl)piperazin-1-yl]-4H-3-thia-4,9-diazabenzof[azulene dihydrochloride 612503-61-4P, (S)-2-Methyl-10-[3-(4-phenylbutyl)-4-methylpiperazin-1-yl]-4H-3-thia-4,9-diazabenzof[azulene dihydrochloride 612503-65-8P, (S)-2-Methyl-10-[3-(3-phenylpropyl)piperazin-1-yl]-4H-3-thia-4,9-diazabenzof[azulene dihydrochloride 612503-66-9P, (S)-2-Methyl-10-[3-(3-phenylpropyl)-4-methylpiperazin-1-yl]-4H-3-thia-4,9-diazabenzof[azulene dihydrochloride 612503-71-6P
 612503-72-7P 612503-73-8P 612503-74-9P
 612503-79-4P 612503-80-7P 612503-93-2P
 612503-94-3P 612503-95-4P 612503-96-5P
 612503-97-6P 612503-98-7P 612503-99-8P
 612504-00-4P 612504-01-5P 612504-02-6P
 612504-03-7P 612504-04-8P 612504-05-9P
 612504-06-0P 612504-54-8P 612504-55-9P
 612504-56-0P 612504-60-6P 612504-61-7P
 612504-62-8P 612504-64-0P 612504-65-1P
 612504-66-2P 612504-67-3P 612504-68-4P
 612504-69-5P 612504-70-8P 612504-72-0P
 612504-73-1P 612504-74-2P 612504-75-3P
 612504-76-4P 612504-77-5P 612504-83-3P
 612504-86-6P 612504-88-8P 612504-93-5P
 612504-96-8P 612504-97-9P 612504-98-0P
 612504-99-1P 612505-00-7P 612505-01-8P
 612505-03-0P 612505-13-2P 612505-14-3P
 612505-18-7P 612505-25-6P 612505-26-7P
 612505-28-9P 612505-29-0P 612505-30-3P
 612505-31-4P 612505-32-5P 612505-33-6P
 612505-34-7P 612505-38-1P 612505-40-5P
 612505-44-9P 612505-45-0P 612505-47-2P
 612505-49-4P 612505-51-8P 612505-58-5P
 612505-59-6P 612505-60-9P 612505-61-0P
 612505-65-4P 612505-67-6P 612505-69-8P
 612505-71-2P 612505-73-4P 612505-75-6P
 612505-77-8P 612505-80-3P 612505-82-5P
 612505-84-7P 612505-86-9P 612505-88-1P
 612505-90-5P 612505-92-7P 612505-94-9P
 612505-95-0P 612505-96-1P 612506-40-8P
 612506-45-3P 612506-57-7P 612506-58-8P
 612506-59-9P 612506-60-2P 612506-61-3P
 612506-62-4P 612506-63-5P 612506-64-6P
 612506-65-7P 612506-66-8P 612506-67-9P
 612506-68-0P 612506-69-1P 612506-70-4P
 612506-71-5P 612506-72-6P 612506-73-7P
 612506-74-8P 612506-75-9P 612506-76-0P
 612506-77-1P 612506-78-2P 612506-79-3P
 612506-80-6P 612506-81-7P 612506-82-8P
 612506-83-9P 612506-84-0P 612506-85-1P
 612506-86-2P 612506-87-3P 612506-88-4P
 612506-89-5P 612506-93-1P 612506-94-2P
 612507-14-9P 612512-52-4P 612512-53-5P
 612512-54-6P 612512-55-7P 612512-59-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(antipsychotic; preparation of aryl-fused benzodiazepine D2 receptor antagonists as antipsychotics)

10/523,147

RN 612502-51-9 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-3-(phenylmethyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612502-52-0 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-3-[[4-[(3-methyl-2-butenyl)oxy]phenyl]methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 612502-53-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612502-54-2 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[(3,4-dimethoxyphenyl)methyl]-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612502-55-3 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-3-[[4-(1-methylethyl)phenyl]methyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612502-56-4 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-3-[(4-phenoxyphenyl)methyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612502-57-5 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-3-(2-naphthalenylmethyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612502-58-6 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-3-(1-naphthalenylmethyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612502-59-7 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-3-[(4-methylphenyl)methyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612502-60-0 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-3-[(3-methylphenyl)methyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612502-61-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[(2-fluorophenyl)methyl]-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612502-62-2 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[(3-fluorophenyl)methyl]-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612502-63-3 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[(4-fluorophenyl)methyl]-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612502-64-4 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-3-[[2-(trifluoromethyl)phenyl]methyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612502-65-5 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[(2-methoxyphenyl)methyl]-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612502-66-6 CAPLUS


CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[(3-methoxyphenyl)methyl]-1-piperazinyl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 612502-67-7 CAPLUS
 CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[(4-methoxyphenyl)methyl]-1-piperazinyl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 612502-68-8 CAPLUS
 CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[(3,4-dichlorophenyl)methyl]-1-piperazinyl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 612502-69-9 CAPLUS
 CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-(1H-indol-3-ylmethyl)-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612502-70-2 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-3-(2-thienylmethyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612502-71-3 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-(benzo[b]thien-3-ylmethyl)-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612502-72-4 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-3-[[3-(1-methylethoxy)phenyl]methyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612502-73-5 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3R)-3-(phenylmethyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612502-74-6 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[(2,4-dimethoxyphenyl)methyl]-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612502-75-7 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[(4-chlorophenyl)methyl]-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612502-76-8 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[(2-chlorophenyl)methyl]-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612502-77-9 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[(3-chlorophenyl)methyl]-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612502-78-0 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[(3,5-difluorophenyl)methyl]-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612502-79-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-3-[(3-(trifluoromethyl)phenyl)methyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612502-81-5 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-4-methyl-3-(2-phenylethyl)-1-piperazinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 612502-82-6 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-4-methyl-3-(phenylmethyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612502-83-7 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-4-methyl-3-[[4-(2-propenyloxy)phenyl]methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 612502-84-8 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-4-methyl-3-(2-pyridinylmethyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612502-85-9 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3R)-4-methyl-3-(phenylmethyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612502-87-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-4-methyl-3-(2-naphthalenylmethyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612502-88-2 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-4-methyl-3-(1-naphthalenylmethyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612502-89-3 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-4-methyl-3-[(4-methylphenyl)methyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612502-90-6 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-4-methyl-3-[(3-methylphenyl)methyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612502-91-7 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[(2-fluorophenyl)methyl]-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612502-92-8 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[(3-fluorophenyl)methyl]-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612502-93-9 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[(4-fluorophenyl)methyl]-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612502-94-0 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-4-methyl-3-[(3-(trifluoromethyl)phenyl)methyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612502-95-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-4-methyl-3-[(2-(trifluoromethyl)phenyl)methyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612502-96-2 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[(2-methoxyphenyl)methyl]-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612502-97-3 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[(3-methoxyphenyl)methyl]-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612502-98-4 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[(3,4-dichlorophenyl)methyl]-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612502-99-5 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-(1H-indol-3-ylmethyl)-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612503-00-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-4-methyl-3-(2-thienylmethyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612503-01-2 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[(2-chlorophenyl)methyl]-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612503-02-3 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[(3-chlorophenyl)methyl]-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612503-03-4 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[(4-chlorophenyl)methyl]-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612503-04-5 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-4-methyl-3-[(4-phenoxyphenyl)methyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612503-05-6 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-4-methyl-3-[(3-phenoxyphenyl)methyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612503-06-7 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-4-methyl-3-[(1-methylethoxy)phenyl)methyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612503-07-8 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[(3,4-dimethoxyphenyl)methyl]-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




10/523,147

RN 612503-15-8 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-3-[2-(2-pyridinyl)ethyl]-1-piperazinyl]-, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●3 HCl

RN 612503-16-9 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-3-[2-(4-pyridinyl)ethyl]-1-piperazinyl]-, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●3 HCl

RN 612503-42-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[2-(4-fluorophenyl)ethyl]-1-piperazinyl]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 612503-43-2 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[2-(3-fluorophenyl)ethyl]-1-piperazinyl]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 612503-44-3 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[2-(2-fluorophenyl)ethyl]-1-piperazinyl]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 612503-45-4 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[2-(4-methoxyphenyl)ethyl]-1-piperazinyl]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 612503-46-5 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[2-(3-methoxyphenyl)ethyl]-1-piperazinyl]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 612503-47-6 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[2-(2-methoxyphenyl)ethyl]-1-piperazinyl]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 612503-48-7 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[2-(4-fluorophenyl)ethyl]-4-methyl-1-piperazinyl]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 612503-49-8 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[2-(3-fluorophenyl)ethyl]-4-methyl-1-piperazinyl]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 612503-50-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[2-(2-fluorophenyl)ethyl]-4-methyl-1-piperazinyl]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 612503-51-2 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[2-(4-methoxyphenyl)ethyl]-4-methyl-1-piperazinyl]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 612503-52-3 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[2-(3-methoxyphenyl)ethyl]-4-methyl-1-piperazinyl]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 612503-53-4 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[2-(2-methoxyphenyl)ethyl]-4-methyl-1-piperazinyl]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 612503-54-5 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-4-methyl-3-[2-(4-pyridinyl)ethyl]-1-piperazinyl]-, trihydrochloride, monohydrate (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●3 HCl

● H₂O

RN 612503-55-6 CAPLUS
 CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-3-[2-(3-pyridinyl)ethyl]-1-piperazinyl]-, trihydrochloride, dihydrate (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●3 HCl

●2 H₂O

RN 612503-56-7 CAPLUS
 CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-4-methyl-3-[2-(3-pyridinyl)ethyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612503-57-8 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-4-methyl-3-[2-(2-pyridinyl)ethyl]-1-piperazinyl]-, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●3 HCl

RN 612503-60-3 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-3-(4-phenylbutyl)-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 612503-61-4 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-4-methyl-3-(4-phenylbutyl)-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 612503-65-8 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-3-(3-phenylpropyl)-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 612503-66-9 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-4-methyl-3-(3-phenylpropyl)-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 612503-71-6 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[(4-bromophenyl)methyl]-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612503-72-7 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[(4-iodophenyl)methyl]-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612503-73-8 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-3-[[4-(2-propenyloxy)phenyl]methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 612503-74-9 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-3-[[4-(1-methylethoxy)phenyl]methyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612503-79-4 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[(4-iodophenyl)methyl]-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612503-80-7 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-4-methyl-3-[[4-(1-methylethoxy)phenyl]methyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612503-93-2 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[(3,5-dimethylphenyl)methyl]-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612503-94-3 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-3-[[4-[(2-methyl-2-propenyl)oxy]phenyl]methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 612503-95-4 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[(2-ethoxyphenyl)methyl]-1-piperazinyl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 612503-96-5 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-3-[[2-(1-

methylethoxy)phenyl)methyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612503-97-6 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-3-(2-pyridinylmethyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612503-98-7 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-4-methyl-3-[[4-[(3-methyl-2-butenyl)oxy]phenyl)methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 612503-99-8 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-(1,3-benzodioxol-5-ylmethyl)-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612504-00-4 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[(3,4-dimethylphenyl)methyl]-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612504-01-5 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-4-methyl-3-[[4-[(2-methyl-2-propenyl)oxy]phenyl)methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 612504-02-6 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-4-methyl-3-[[4-(1-methylethyl)phenyl]methyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612504-03-7 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[(3,5-dimethylphenyl)methyl]-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612504-04-8 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[(2-ethoxyphenyl)methyl]-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612504-05-9 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-([1,1'-biphenyl]-4-ylmethyl)-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612504-06-0 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-4-methyl-3-[[2-(1-methylethoxy)phenyl]methyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612504-54-8 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[2-(4-chlorophenyl)ethyl]-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612504-55-9 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[2-(3-chlorophenyl)ethyl]-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612504-56-0 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[2-(2-chlorophenyl)ethyl]-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612504-60-6 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-4-methyl-3-[2-[4-(trifluoromethyl)phenyl]ethyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612504-61-7 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-4-methyl-3-[2-[2-(trifluoromethyl)phenyl]ethyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612504-62-8 CAPLUS


CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-4-methyl-3-[2-[3-(trifluoromethyl)phenyl]ethyl]-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 612504-64-0 CAPLUS


CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[3-[2-(2,4-difluorophenyl)ethyl]-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)



RN 612504-65-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 8-fluoro-4-[(3S)-3-[2-(3-fluorophenyl)ethyl]-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612504-66-2 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 8-fluoro-4-[(3S)-3-[2-(4-methoxyphenyl)ethyl]-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612504-67-3 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 7-fluoro-4-[(3S)-3-[2-(3-fluorophenyl)ethyl]-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612504-68-4 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 7-fluoro-4-[(3S)-3-[2-(4-methoxyphenyl)ethyl]-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612504-69-5 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 8-fluoro-4-[(3S)-3-[2-(3-fluorophenyl)ethyl]-1-piperazinyl]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 612504-70-8 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 8-fluoro-4-[(3S)-3-[2-(4-

methoxyphenyl)ethyl]-4-methyl-1-piperaziny]-2-methyl-, monohydrochloride
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 612504-72-0 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 7-fluoro-4-[(3S)-3-[2-(3-fluorophenyl)ethyl]-4-methyl-1-piperaziny]-2-methyl-, monohydrochloride
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 612504-73-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 7-fluoro-4-[(3S)-3-[2-(4-methoxyphenyl)ethyl]-4-methyl-1-piperaziny]-2-methyl-, monohydrochloride
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 612504-74-2 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-ethyl-7-fluoro-4-[(3S)-3-[2-(3-fluorophenyl)ethyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612504-75-3 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-ethyl-7-fluoro-4-[(3S)-3-[2-(3-fluorophenyl)ethyl]-4-methyl-1-piperazinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 612504-76-4 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-ethyl-7-fluoro-4-[(3S)-3-[2-(4-methoxyphenyl)ethyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612504-77-5 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-ethyl-7-fluoro-4-[(3S)-3-[2-(4-methoxyphenyl)ethyl]-4-methyl-1-piperazinyl]-, monohydrochloride (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 612504-83-3 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-4-methyl-3-[2-(1-naphthalenyl)ethyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612504-86-6 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-3-[2-(2-naphthalenyl)ethyl]-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 612504-88-8 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-4-methyl-3-[2-(2-

naphthalenyl)ethyl]-1-piperazinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 612504-93-5 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[2-(3-furanyl)ethyl]-4-methyl-1-piperazinyl]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 612504-96-8 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-3-[2-(3-thienyl)ethyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612504-97-9 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-4-methyl-3-[2-(3-thienyl)ethyl]-1-piperazinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 612504-98-0 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-(1-methylethyl)-4-[(3S)-3-(phenylmethyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612504-99-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-(1-methylethyl)-4-[(3S)-3-(2-phenylethyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612505-00-7 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[(2-methoxyphenyl)methyl]-1-piperazinyl]-2-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 612505-01-8 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-(1-methylethyl)-4-[(3S)-4-methyl-3-(2-phenylethyl)-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 612505-03-0 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-(1,1-dimethylethyl)-4-[(3S)-4-methyl-3-(2-phenylethyl)-1-piperazinyl]-, monohydrochloride (9CI) (CA

10/523,147

INDEX NAME)

Absolute stereochemistry.




● HCl

RN 612505-13-2 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-methyl-10-[(3S)-3-(2-phenylethyl)-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 612505-14-3 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-methyl-10-[(3S)-4-methyl-3-(2-phenylethyl)-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●2 HCl

RN 612505-18-7 CAPLUS
 CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-[2-(4-methoxyphenyl)ethyl]-4-methyl-1-piperazinyl]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●2 HCl

RN 612505-25-6 CAPLUS
 CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-methyl-10-[(3S)-4-methyl-3-(phenylmethyl)-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●2 HCl

RN 612505-26-7 CAPLUS
 CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-[(2-methoxyphenyl)methyl]-4-methyl-1-piperazinyl]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●2 HCl

RN 612505-28-9 CAPLUS
 CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-(1-methylethyl)-10-[(3S)-4-methyl-3-(2-phenylethyl)-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 612505-29-0 CAPLUS
 CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-[2-(4-methoxyphenyl)ethyl]-4-methyl-1-piperazinyl]-2-(1-methylethyl)-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 612505-30-3 CAPLUS
 CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-(1-methylethyl)-10-[(3S)-4-methyl-3-(phenylmethyl)-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●2 HCl

RN 612505-31-4 CAPLUS
 CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-[2-(4-fluorophenyl)ethyl]-4-methyl-1-piperazinyl]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●2 HCl

RN 612505-32-5 CAPLUS
 CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-[2-(3-fluorophenyl)ethyl]-4-methyl-1-piperazinyl]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 612505-33-6 CAPLUS
 CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-[2-(3-fluorophenyl)ethyl]-4-methyl-1-piperazinyl]-2-(1-methylethyl)-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 612505-34-7 CAPLUS
 CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-[2-(4-fluorophenyl)ethyl]-4-methyl-1-piperazinyl]-2-(1-methylethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 612505-38-1 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-butyl-10-[(3S)-3-(2-phenylethyl)-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 612505-40-5 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-butyl-10-[(3S)-4-methyl-3-(2-phenylethyl)-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 612505-44-9 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-cyclopentyl-10-[(3S)-3-(2-phenylethyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612505-45-0 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-cyclopentyl-10-[(3S)-4-methyl-3-(2-phenylethyl)-1-piperazinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 612505-47-2 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-cyclopentyl-10-[(3S)-4-methyl-3-(phenylmethyl)-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 612505-49-4 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-cyclopentyl-10-[(3S)-3-[2-(3-methoxyphenyl)ethyl]-4-methyl-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 612505-51-8 CAPLUS
CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-cyclopentyl-10-[(3S)-3-[2-(4-methoxyphenyl)ethyl]-4-methyl-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 612505-58-5 CAPLUS
CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-ethyl-10-[(3S)-3-[2-(4-methoxyphenyl)ethyl]-4-methyl-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 612505-59-6 CAPLUS
CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-ethyl-10-[(3S)-3-[2-(4-fluorophenyl)ethyl]-4-methyl-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 612505-60-9 CAPLUS
CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-ethyl-10-[(3S)-3-[2-(3-fluorophenyl)ethyl]-4-methyl-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 612505-61-0 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-ethyl-10-[(3S)-3-[2-(3-methoxyphenyl)ethyl]-4-methyl-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 612505-65-4 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-[2-(3-fluorophenyl)ethyl]-1-piperazinyl]-2-(trifluoromethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 612505-67-6 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-[2-(4-fluorophenyl)ethyl]-1-piperazinyl]-2-(trifluoromethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 612505-69-8 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-[2-(3-methoxyphenyl)ethyl]-1-piperazinyl]-2-(trifluoromethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 612505-71-2 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-[2-(4-methoxyphenyl)ethyl]-1-piperazinyl]-2-(trifluoromethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 612505-73-4 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-[2-(3-fluorophenyl)ethyl]-4-methyl-1-piperazinyl]-2-(trifluoromethyl)-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 612505-75-6 CAPLUS
 CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-[2-(4-methoxyphenyl)ethyl]-4-methyl-1-piperazinyl]-2-(trifluoromethyl)-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 612505-77-8 CAPLUS
 CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-[2-(4-fluorophenyl)ethyl]-4-methyl-1-piperazinyl]-2-(trifluoromethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 612505-80-3 CAPLUS

CN 6H-[1]Benzothieno[2,3-b][1,5]benzodiazepine, 8-fluoro-12-[(3S)-4-methyl-3-(2-phenylethyl)-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 612505-82-5 CAPLUS

CN 6H-[1]Benzothieno[2,3-b][1,5]benzodiazepine, 8-fluoro-12-[(3S)-3-[2-(4-methoxyphenyl)ethyl]-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 612505-84-7 CAPLUS

CN 6H-[1]Benzothieno[2,3-b][1,5]benzodiazepine, 8-fluoro-12-[(3S)-3-[2-(3-methoxyphenyl)ethyl]-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 612505-86-9 CAPLUS

CN 6H-[1]Benzothieno[2,3-b][1,5]benzodiazepine, 8-fluoro-12-[(3S)-3-[2-(3-fluorophenyl)ethyl]-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 612505-88-1 CAPLUS

CN 6H-[1]Benzothieno[2,3-b][1,5]benzodiazepine, 8-fluoro-12-[(3S)-3-[2-(4-fluorophenyl)ethyl]-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 612505-90-5 CAPLUS

CN 6H-[1]Benzothieno[2,3-b][1,5]benzodiazepine, 8-fluoro-12-[(3S)-3-[2-(4-methoxyphenyl)ethyl]-4-methyl-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 612505-92-7 CAPLUS
CN 6H-[1]Benzothieno[2,3-b][1,5]benzodiazepine, 8-fluoro-12-[(3S)-3-[2-(3-methoxyphenyl)ethyl]-4-methyl-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 612505-94-9 CAPLUS
CN 6H-[1]Benzothieno[2,3-b][1,5]benzodiazepine, 8-fluoro-12-[(3S)-3-[2-(3-fluorophenyl)ethyl]-4-methyl-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 612505-95-0 CAPLUS

CN 6H-[1]Benzothieno[2,3-b][1,5]benzodiazepine, 8-fluoro-12-[(3S)-3-[2-(4-fluorophenyl)ethyl]-4-methyl-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612505-96-1 CAPLUS

CN 6H-[1]Benzothieno[2,3-b][1,5]benzodiazepine, 8-fluoro-12-[(3S)-3-[2-(4-fluorophenyl)ethyl]-4-methyl-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 612506-40-8 CAPLUS

CN 2-Piperazineethanol, 4-(2-methyl-10H-thieno[2,3-b][1,5]benzodiazepin-4-yl)-
α-phenyl-, (αR,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 612506-45-3 CAPLUS

CN 2-Piperazineethanol, 1-methyl-4-[2-(1-methylethyl)-10H-thieno[2,3-
b][1,5]benzodiazepin-4-yl]-α-phenyl-, (αS,2S)- (CA INDEX
NAME)


Absolute stereochemistry.



RN 612506-57-7 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-3-[2-(2-pyridinyl)ethyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612506-58-8 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-3-[2-(4-pyridinyl)ethyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612506-59-9 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[2-(4-fluorophenyl)ethyl]-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612506-60-2 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[2-(2-fluorophenyl)ethyl]-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612506-61-3 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[2-(4-methoxyphenyl)ethyl]-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612506-62-4 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[2-(3-methoxyphenyl)ethyl]-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612506-63-5 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[2-(2-methoxyphenyl)ethyl]-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612506-64-6 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[2-(4-methoxyphenyl)ethyl]-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612506-65-7 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[2-(3-fluorophenyl)ethyl]-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612506-66-8 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[2-(2-fluorophenyl)ethyl]-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612506-67-9 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[2-(4-methoxyphenyl)ethyl]-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612506-68-0 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[2-(3-methoxyphenyl)ethyl]-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612506-69-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[2-(2-methoxyphenyl)ethyl]-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612506-70-4 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-4-methyl-3-[2-(4-pyridinyl)ethyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612506-71-5 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-3-[2-(3-pyridinyl)ethyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612506-72-6 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-4-methyl-3-[2-(2-pyridinyl)ethyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612506-73-7 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-3-[(3-phenoxyphenyl)methyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612506-74-8 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 8-fluoro-4-[(3S)-3-[2-(4-methoxyphenyl)ethyl]-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612506-75-9 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 7-fluoro-4-[(3S)-3-[2-(3-fluorophenyl)ethyl]-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612506-76-0 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 7-fluoro-4-[(3S)-3-[2-(4-methoxyphenyl)ethyl]-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612506-77-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-ethyl-7-fluoro-4-[(3S)-3-[2-(3-fluorophenyl)ethyl]-4-methyl-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612506-78-2 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-4-methyl-3-[2-(3-fluorophenyl)ethyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612506-79-3 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[(2-methoxyphenyl)methyl]-4-methyl-1-piperazinyl]-2-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 612506-80-6 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-(1,1-dimethylethyl)-4-[(3S)-4-methyl-3-(2-phenylethyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612506-81-7 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-methyl-10-[(3S)-4-methyl-3-(phenylmethyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612506-82-8 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-[(2-methoxyphenyl)methyl]-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 612506-83-9 CAPLUS

10/523,147

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-(1-methylethyl)-10-[(3S)-4-methyl-3-(2-phenylethyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612506-84-0 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-[2-(4-methoxyphenyl)ethyl]-4-methyl-1-piperazinyl]-2-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 612506-85-1 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-(1-methylethyl)-10-[(3S)-4-methyl-3-(phenylmethyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612506-86-2 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-[2-(4-fluorophenyl)ethyl]-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612506-87-3 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-[2-(3-fluorophenyl)ethyl]-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 612506-88-4 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-[2-(3-fluorophenyl)ethyl]-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)

10/523,147

NAME)


Absolute stereochemistry.



RN 612506-89-5 CAPLUS


CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-[2-(4-fluorophenyl)ethyl]-4-methyl-1-piperazinyl]-2-(1-methylethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 612506-93-1 CAPLUS


CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[3-[2-(3-furanyl)ethyl]-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)



RN 612506-94-2 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-[(4-methoxyphenyl)methyl]-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612507-14-9 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-(1-methylethyl)-4-[(3S)-4-methyl-3-(phenylmethyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612512-52-4 CAPLUS


CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[(4-methoxyphenyl)methyl]-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 612512-53-5 CAPLUS
 CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-3-(3-thienylmethyl)-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 612512-54-6 CAPLUS
 CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[(4-bromophenyl)methyl]-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 612512-55-7 CAPLUS
 CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-(benzo[b]thien-3-ylmethyl)-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612512-59-1 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-[2-(3-methoxyphenyl)ethyl]-4-methyl-1-piperazinyl]-2-(trifluoromethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

IT 612503-67-0P 612503-68-1P 612503-69-2P


612503-70-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(antipsychotic; preparation of aryl-fused benzodiazepine D2 receptor antagonists as antipsychotics)

RN 612503-67-0 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-3-(4-phenylbutyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612503-68-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-4-methyl-3-(4-phenylbutyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612503-69-2 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-3-(3-phenylpropyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612503-70-5 CAPLUS


CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-[(3S)-4-methyl-3-(3-phenylpropyl)-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.




IT 612507-18-3P 612507-19-4P 612507-20-7P
 612507-23-0P 612507-24-1P 612507-26-3P
 612507-28-5P 612507-31-0P 612507-32-1P
 612507-33-2P 612507-34-3P 612507-35-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (intermediate; preparation of aryl-fused benzodiazepine D2 receptor
 antagonists as antipsychotics)
 RN 612507-18-3 CAPLUS
 CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-methyl-10-[(3S)-3-(2-phenylethyl)-
 1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 612507-19-4 CAPLUS
 CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-methyl-10-[(3S)-4-methyl-3-(2-
 phenylethyl)-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 612507-20-7 CAPLUS
 CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 10-[(3S)-3-[2-(4-
 methoxyphenyl)ethyl]-4-methyl-1-piperazinyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 612507-23-0 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-cyclopentyl-10-[(3S)-4-methyl-3-(2-phenylethyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612507-24-1 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-cyclopentyl-10-[(3S)-4-methyl-3-(phenylmethyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612507-26-3 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-cyclopentyl-10-[(3S)-3-[2-(3-methoxyphenyl)ethyl]-4-methyl-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612507-28-5 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-cyclopentyl-10-[(3S)-3-[2-(4-methoxyphenyl)ethyl]-4-methyl-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612507-31-0 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-ethyl-10-[(3S)-3-[2-(4-methoxyphenyl)ethyl]-4-methyl-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612507-32-1 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-ethyl-10-[(3S)-3-[2-(4-fluorophenyl)ethyl]-4-methyl-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612507-33-2 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-ethyl-10-[(3S)-3-[2-(3-fluorophenyl)ethyl]-4-methyl-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 612507-34-3 CAPLUS

CN 4H-Thiazolo[5,4-b][1,5]benzodiazepine, 2-ethyl-10-[(3S)-3-[2-(3-methoxyphenyl)ethyl]-4-methyl-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.




10/523,147

RN 612507-35-4 CAPLUS

CN 6H-[1]Benzothieno[2,3-b][1,5]benzodiazepine, 8-fluoro-12-[(3S)-4-methyl-3-(2-phenylethyl)-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.




IT 612506-98-6

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of aryl-fused benzodiazepine D2 receptor antagonists as antipsychotics)

RN 612506-98-6 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-[(3S)-3-[2-(3-fluorophenyl)ethyl]-1-piperazinyl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT:


7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1982:520116 CAPLUS
 DOCUMENT NUMBER: 97:120116
 ORIGINAL REFERENCE NO.: 97:19780h,19781a
 TITLE: Effects of conformationally restricted
 4-piperazinyl-10H-thienobenzodiazepine neuroleptics on
 central dopaminergic and cholinergic systems
 AUTHOR(S): Chakrabarti, Jiban K.; Hotten, Terrence M.; Morgan,
 Sarah E.; Pullar, Ian A.; Rackham, David M.; Risius,
 Francesca C.; Wedley, Susan; Chaney, Michael O.;
 Jones, Noel D.
 CORPORATE SOURCE: Lilly Res. Cent. Ltd., Windlesham/Surrey, GU20 6PH, UK
 SOURCE: Journal of Medicinal Chemistry (1982), 25(10), 1133-40
 CODEN: JMCMAR; ISSN: 0022-2623
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB The levels of antidopaminergic and anticholinergic activities of the
 4-piperazinyl-10H-thienobenzodiazepine neuroleptics I (R, R1, and R2 = H
 or Me; R3 = H, Me, or Et; R4 = H, Me, Et, or CHMe2), are modulated by
 imposing steric impedance to the piperazine ring. The optimum situation
 in favor of the anticholinergic action is reached in I (R = R1 = R2 = H,
 R3 = R4 = Me), where activity equivalent to hyoscyne, as measured by the
 [3H]quinuclidinyl benzylate receptor binding assay, is obtained. The
 structure-activity relations indicate the importance of certain spatial
 dispositions of the distal piperazine N (electron lone pair) with respect
 to the tricyclic system. The conformational aspects of I binding to the
 relevant receptors are discussed.
 IT 82546-79-0 82546-80-3 82546-81-4
 RL: BIOL (Biological study)
 (antidopaminergic and anticholinergic activity of, structure in
 relation to)
 RN 82546-79-0 CAPLUS
 CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 4-(3,4-dimethyl-1-piperazinyl)-2-
 ethyl-7-fluoro- (CA INDEX NAME)




RN 82546-80-3 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-ethyl-7-fluoro-4-(3,4,5-trimethyl-1-piperazinyl)- (CA INDEX NAME)



RN 82546-81-4 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-ethyl-7-fluoro-4-(2,4,5-trimethyl-1-piperazinyl)- (CA INDEX NAME)



10/523,147

=> => d his

(FILE 'HOME' ENTERED AT 13:07:18 ON 14 DEC 2007)

FILE 'REGISTRY' ENTERED AT 13:07:32 ON 14 DEC 2007

L1 STRUCTURE UPLOADED
L2 44 S L1
L3 STRUCTURE UPLOADED
L4 26 S L3
L5 946 S L1 SSS FUL
L6 545 S L3 SUB=L5 FUL
L7 540 S L6 AND CAPLUS/LC
L8 5 S L6 NOT L7

FILE 'CAPLUS' ENTERED AT 13:19:34 ON 14 DEC 2007

L9 5 S L6


FILE 'REGISTRY' ENTERED AT 13:21:58 ON 14 DEC 2007

=> d 18 5

10/523,147

L8 ANSWER 5 OF 5 REGISTRY COPYRIGHT 2007 ACS on STN
RN 746603-80-5 REGISTRY
ED Entered STN: 17 Sep 2004
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-ethyl-7-fluoro-4-[(3S)-3-[2-(4-methoxyphenyl)ethyl]-4-methyl-1-piperazinyl]- (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H31 F N4 O S
CI COM
SR CA

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/523,147

=>